{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:08:30Z","timestamp":1791418110443,"version":"4.3.3"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,5,10]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p>Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and\/or refractory follicular or marginal zone lymphoma. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per independent radiology review.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo plus rituximab (n = 180). Infections (63% v 49%), neutropenia (58% v 23%), and cutaneous reactions (32% v 12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 neutropenia (50% v 13%) and leukopenia (7% v 2%) were higher with lenalidomide plus rituximab; no other grade 3 or 4 adverse event differed by 5% or more between groups. Progression-free survival was significantly improved for lenalidomide plus rituximab versus placebo plus rituximab, with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P &lt; .001) and median duration of 39.4 months (95% CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to 16.7 months), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.00010","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T19:59:18Z","timestamp":1553198358000},"page":"1188-1199","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":413,"title":["AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma"],"prefix":"10.1200","volume":"37","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"Charles University, General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center, Shanghai, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Institute, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Tianjin, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Ghent University Hospital, Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Scheliga","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Re","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria di Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Fogliatto","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"Hospital A Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Moreira","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil Epe, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Cabe\u00e7adas","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Kalambakas","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fustier","sequence":"additional","affiliation":[{"name":"Celgene International, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the AUGMENT Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","volume-title":"World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH CE","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-516815"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.54.31"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-625004"},{"key":"B16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"Reddy N","year":"2008","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.561"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8049"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7563"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy286.014"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2221"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12755"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq195"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3968"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T01:04:24Z","timestamp":1721091864000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,5,10]]}},"alternative-id":["10.1200\/JCO.19.00010"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.00010","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"2019-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}